Shots:

• Hansa to receive $10M up front- up to $397.5M as development- regulatory & commercial milestones. Hansa will book all sales of therapy and will get royalties on gene therapy sales that arises from treating Ab-positive patients enabled through imlifidase pre-treatment
• Sarepta get an exclusive WW license to develop and promote imlifidase as a pre-treatment for gene therapy in DMD & LGDM patients who have pre-existing antibodies to AAV
• Imlifidase is an Ab-cleaving enzyme targeting IgG- inhibits an IgG-mediated immune response and has rapid onset of action within hours after administration- thus clearing the AAV-IgG Abs typically preclude dosing or re-dosing with AAV

Click here to read full press release/ article | Ref: Sarepta | Image: Wall Street Nation